ImmunityBio, Inc. (IBRX)
Health Care ยท Biological Products, (No Diagnostic Substances)
ImmunityBio, Inc. (IBRX) is listed on Nasdaq, where its shares have traded since March 10, 2021. SentiSense covers ImmunityBio, Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances). Richard Adcock is its chief executive officer. The company reports 691 employees, and its corporate website is www.immunitybio.com.
About ImmunityBio, Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 393 institutions reported holding IBRX, with 201.2 million shares worth $1.8 billion in aggregate. The largest reported holders were Vanguard, BlackRock and State Street. Of the 5 largest reported holders, 4 added shares and 1 reduced its position during the quarter.
More on IBRX
- IBRX sentiment: whether news and social coverage of ImmunityBio, Inc. leans bullish or bearish, and the stories driving it.
- IBRX ownership: all 393 reporting institutions, plus insider and congressional trades.
- IBRX financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for ImmunityBio, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does ImmunityBio, Inc. do?
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases.
What sector is IBRX in?
SentiSense classifies ImmunityBio, Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where does IBRX stock trade?
ImmunityBio, Inc. (IBRX) is listed on Nasdaq, where its shares have traded since March 10, 2021.
Who is the CEO of ImmunityBio, Inc.?
Richard Adcock is the chief executive officer of ImmunityBio, Inc..